Tumor lysis syndrome overview: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Tumor lysis syndrome}} | {{Tumor lysis syndrome}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | |||
== Overview == | |||
In [[medicine]] ([[oncology]] and [[hematology]]), '''tumor lysis syndrome''' ('''TLS''') is a group of [[metabolism|metabolic]] complications that can occur after treatment of [[cancer]], usually [[lymphoma]]s and [[leukemia]]s, and sometimes even without treatment. These complications are caused by the break-down products of dying cancer cells and include [[hyperkalemia]], [[hyperphosphatemia]], [[hyperuricemia]], [[hypocalcemia]], and [[acute renal failure]]. | In [[medicine]] ([[oncology]] and [[hematology]]), '''tumor lysis syndrome''' ('''TLS''') is a group of [[metabolism|metabolic]] complications that can occur after treatment of [[cancer]], usually [[lymphoma]]s and [[leukemia]]s, and sometimes even without treatment. These complications are caused by the break-down products of dying cancer cells and include [[hyperkalemia]], [[hyperphosphatemia]], [[hyperuricemia]], [[hypocalcemia]], and [[acute renal failure]]. | ||
Revision as of 19:20, 21 September 2015
|
Tumor lysis syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tumor lysis syndrome overview On the Web |
|
American Roentgen Ray Society Images of Tumor lysis syndrome overview |
|
Risk calculators and risk factors for Tumor lysis syndrome overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
In medicine (oncology and hematology), tumor lysis syndrome (TLS) is a group of metabolic complications that can occur after treatment of cancer, usually lymphomas and leukemias, and sometimes even without treatment. These complications are caused by the break-down products of dying cancer cells and include hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, and acute renal failure.